侵袭性非霍奇金淋巴瘤规范治疗的演化
摘要
本文系统回顾了以弥漫大B细胞性淋巴瘤为主的侵袭性非霍奇金淋巴瘤治疗方案CHOP的由来及其演化，比较分析了侵袭性非霍奇金淋巴瘤多种治疗方案的优点及不足之处，明确了方案选择的依据。
出处
《国际输血及血液学杂志》
CAS
2009年第5期421-424,共4页
International Journal of Blood Transfusion and Hematology
参考文献30
-
1Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood, 2004, 104(5): 1258-1265.
-
2Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediateor low risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vineristine, and prednisone (RCHOP) with respect to treatment outcome. Blood, 2006, 108(5): 1504-1508.
-
3Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 1993, 328(14): 1002-1006.
-
4Pfreundschuh M, Trtimper L, Kloess M, et al. Two-weekly or 3- weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 2004,104(3): 626-633.
-
5Pfreundschuh M, Tramper L, Kloess M, et al. Two weekly or 3 weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHLB2 trialof the DSHNHL. Blood, 2004,104(3): 634-641.
-
6Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol, 2003, 14(6): 881-893.
-
7Verdonck LF, Notenboom A, de Jong DD, et al. Intensi;ied 12- week CHOP (I-CHOP) plus G CSF compared with standard 24- week CHOP (CHOP-21) for patients with intermediate-risk aggressive non Hodgkin lymphoma: a phase 3 trial of the Dutch- Belgian Hemato Ontology Cooperative Group (HOVON). Blood, 2007, 109(7) : 2759-2766.
-
8Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase Ⅱ study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol, 2003,21(13) : 2466-2473.
-
9Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin' s lymphoma: final analysis of the prospective LNH87-2 protoeol-a groupe d'Etude des lymphomes de l'Aduhe study. J Cliu Oneol, 2000,18(16): 3025-3030.
-
10Oreb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev, 2007,33(4) : 338-346.
-
1俸瑞发.乳腺癌分子分型的研究进展[J].河南中医,2013,33(B10):481-482.
-
2李利,辛育龄.人胸导管由来LAK细胞的生物特性及其体外抗...[J].中华微生物学和免疫学杂志,1992,12(6):383-386. 被引量：3
-
3韩以轩.癌细胞的由来[J].中华养生保健,2015,0(2):4-5.
-
4李英（编译）.关注手机与癌症的关系[J].癌症康复,2010(1):50-50.
-
5杨占民,张帆.胃肠道间质瘤研究进展[J].健康导报（医学版）,2015,20(12):59-60.
-
6王其彰.食管良性病会议的由来[J].食管外科电子杂志,2013(3):95-96.
-
7陈国芳,刘超.桥本甲状腺炎伴甲状腺乳头状癌：因果或是偶然？[J].中华内分泌代谢杂志,2013,29(12):1006-1009. 被引量：13
-
8中国发现肝癌基因[J].中老年保健,2010(10):6-6.
-
9许英晨,岳文,裴雪涛.肿瘤干细胞与表观遗传学调控[J].生命科学,2009,21(5):720-723.
-
10何裕民.治癌新理念：与癌“和平共处”[J].老同志之友（上半月）,2006,0(10):46-47.
